The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis
The DOI matches its Crossref record.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although CQ does not affect dormant hypnozoites, it suppresses relapse for up to 28 days [38], after which PQ helps prevent further relapses [39].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 65
- Coatney, 1963, Pitfalls in a discovery: the chronicle of chloroquine, Am J Trop Med Hyg, 12, 121, 10.4269/ajtmh.1963.12.121 · DOI · Paper page
- Baird, 2004, Chloroquine resistance in Plasmodium vivax, Antimicrob Agents Chemother, 48, 4075, 10.1128/AAC.48.11.4075-4083.2004 · DOI · Paper page
- Rieckmann, 1989, Plasmodium vivax resistance to chloroquine?, Lancet, 2, 1183, 10.1016/S0140-6736(89)91792-3 · DOI · Paper page
- Wellems, 2001, Chloroquine-resistant malaria, J Infect Dis, 184, 770, 10.1086/322858 · DOI · Paper page
- Price, 2014, Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis, Lancet Infect Dis, 14, 982, 10.1016/S1473-3099(14)70855-2 · DOI · Paper page
- Douglas, 2013, Major burden of severe anemia from non-falciparum malaria species in southern Papua: a hospital-based surveillance study, PLoS Med, 10, e1001575, 10.1371/journal.pmed.1001575 · DOI · Paper page
- Price, 2009, New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance, Curr Opin Infect Dis, 22, 430, 10.1097/QCO.0b013e32832f14c1 · DOI · Paper page
- Douglas, 2012, Chemotherapeutic strategies for reducing transmission of Plasmodium vivax malaria, Adv Parasitol, 80, 271, 10.1016/B978-0-12-397900-1.00005-0 · DOI
- Egan, 2007, Strategies to reverse drug resistance in malaria, Curr Opin Infect Dis, 20, 598, 10.1097/QCO.0b013e3282f1673a · DOI
- Berliner, 1948, Studies on the chemotherapy of the human malarias. Vi. The physiological disposition, antimalarial activity, and toxicity of several derivatives of 4-aminoquinoline, J Clin Invest, 27, 98, 10.1172/JCI101980 · doi:10.1172/jci101980
- Abreha, 2017, Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial, PLoS Med, 14, e1002299, 10.1371/journal.pmed.1002299 · DOI · Paper page
- Luxemburger, 1999, Treatment of vivax malaria on the western border of Thailand, Trans R Soc Trop Med Hyg, 93, 433, 10.1016/S0035-9203(99)90149-9 · DOI
- Commons, 2017, The Vivax Surveyor: online mapping database for Plasmodium vivax clinical trials, Int J Parasitol Drugs Drug Resist, 7, 181, 10.1016/j.ijpddr.2017.03.003 · DOI
- Gething, 2012, A long neglected world malaria map: Plasmodium vivax endemicity in 2010, PLoS Negl Trop Dis, 6, e1814, 10.1371/journal.pntd.0001814 · DOI · Paper page
- Battle, 2014, Geographical variation in Plasmodium vivax relapse, Malar J, 13, 144, 10.1186/1475-2875-13-144 · DOI · Paper page
- Taylor, 2001, Chloroquine/doxycycline combination versus chloroquine alone, and doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in northeastern Irian Jaya, Indonesia, Am J Trop Med Hyg, 64, 223, 10.4269/ajtmh.2001.64.223 · DOI
- Phan, 2002, Artemisinin or chloroquine for blood stage Plasmodium vivax malaria in Vietnam, Trop Med Int Health, 7, 858, 10.1046/j.1365-3156.2002.00948.x · DOI
- Valecha, 2006, Therapeutic efficacy of chloroquine in Plasmodium vivax from areas with different epidemiological patterns in India and their Pvdhfr gene mutation pattern, Trans R Soc Trop Med Hyg, 100, 831, 10.1016/j.trstmh.2005.11.012 · DOI
- Leslie, 2007, Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial, JAMA, 297, 2201, 10.1001/jama.297.20.2201 · doi:10.1001/jama.297.20.2201
- Ratcliff, 2007, Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia, Trans R Soc Trop Med Hyg, 101, 351, 10.1016/j.trstmh.2006.06.008 · DOI · Paper page
- Guthmann, 2008, Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar, Trop Med Int Health, 13, 91, 10.1111/j.1365-3156.2007.01978.x · DOI
- Leslie, 2008, A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan, PLoS One, 3, e2861, 10.1371/journal.pone.0002861 · DOI
- Ketema, 2009, Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia, Malar J, 8, 177, 10.1186/1475-2875-8-177 · DOI
- Sutanto, 2009, Resistance to chloroquine by Plasmodium vivax at Alor in the Lesser Sundas Archipelago in eastern Indonesia, Am J Trop Med Hyg, 81, 338, 10.4269/ajtmh.2009.81.338 · doi:10.4269/ajtmh.2009.81.338
- Awab, 2010, Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial, Malar J, 9, 105, 10.1186/1475-2875-9-105 · DOI
- Sutanto, 2010, Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia, Malar J, 9, 52, 10.1186/1475-2875-9-52 · DOI
- Phyo, 2011, Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial, Clin Infect Dis, 53, 977, 10.1093/cid/cir631 · DOI · Paper page
- Poravuth, 2011, Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial, PLoS One, 6, e14501, 10.1371/journal.pone.0014501 · DOI
- Mishra, 2012, Monitoring antimalarial drug resistance in India via sentinel sites: outcomes and risk factors for treatment failure, 2009–2010, Bull World Health Organ, 90, 895, 10.2471/BLT.12.109124 · DOI
- Barber, 2013, A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy, Clin Infect Dis, 56, 383, 10.1093/cid/cis902 · DOI · Paper page
- Hwang, 2013, In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia, PLoS One, 8, e63433, 10.1371/journal.pone.0063433 · doi:10.1371/journal.pone.0063433
- Marques, 2014, Plasmodium vivax chloroquine resistance and anemia in the western Brazilian Amazon, Antimicrob Agents Chemother, 58, 342, 10.1128/AAC.02279-12 · DOI
- Anez, 2015, Resistance of infection by Plasmodium vivax to chloroquine in Bolivia, Malar J, 14, 261, 10.1186/s12936-015-0774-4 · DOI
- Getachew, 2015, Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia, Malar J, 14, 525, 10.1186/s12936-015-1041-4 · DOI · Paper page
- Gomes, 2015, Efficacy in the treatment of malaria by Plasmodium vivax in Oiapoque, Brazil, on the border with French Guiana: the importance of control over external factors, Malar J, 14, 402, 10.1186/s12936-015-0925-7 · doi:10.1186/s12936-015-0925-7
- Gonzalez-Ceron, 2015, Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico, Malar J, 14, 426, 10.1186/s12936-015-0938-2 · DOI
- Lidia, 2015, Therapeutic effects of dyhidroartemisinin piperaquine versus chloroquine for uncomplicated vivax malaria in Kupang, East Nusa Tenggara, Indonesia, Int J Pharm Sci Rev Res, 31, 247
- Rishikesh, 2015, Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India, Malar J, 14, 310, 10.1186/s12936-015-0824-y · DOI
- Thanh, 2015, Confirmed Plasmodium vivax resistance to chloroquine in central Vietnam, Antimicrob Agents Chemother, 59, 7411, 10.1128/AAC.00791-15 · DOI
- Grigg, 2016, Efficacy of artesunate-mefloquine for chloroquine-resistant Plasmodium vivax malaria in Malaysia: an open-label, randomized, controlled trial, Clin Infect Dis, 62, 1403, 10.1093/cid/ciw121 · DOI
- Ley, 2016, G6PD deficiency and antimalarial efficacy for uncomplicated malaria in Bangladesh: a prospective observational study, PLoS One, 11, e0154015, 10.1371/journal.pone.0154015 · DOI
- Pereira, 2016, Safety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: a step towards a user-friendly malaria vivax treatment, Malar J, 15, 477, 10.1186/s12936-016-1530-0 · DOI
- Saravu, 2016, Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from primary care centres in southwestern India, PLoS One, 11, e0157666, 10.1371/journal.pone.0157666 · DOI · Paper page
- Thuan, 2016, A randomized comparison of chloroquine versus dihydroartemisinin-piperaquine for the treatment of Plasmodium vivax infection in Vietnam, Am J Trop Med Hyg, 94, 879, 10.4269/ajtmh.15-0740 · doi:10.4269/ajtmh.15-0740
- Wangchuk, 2016, Where chloroquine still works: the genetic make-up and susceptibility of Plasmodium vivax to chloroquine plus primaquine in Bhutan, Malar J, 15, 277, 10.1186/s12936-016-1320-8 · DOI
- Zuluaga-Idarraga, 2016, Prospective study of Plasmodium vivax malaria recurrence after radical treatment with a chloroquine-primaquine standard regimen in Turbo, Colombia, Antimicrob Agents Chemother, 60, 4610, 10.1128/AAC.00186-16 · DOI
- Siqueira, 2017, Fixed-dose artesunate-amodiaquine combination vs chloroquine for treatment of uncomplicated blood stage P. vivax infection in the Brazilian Amazon: an open-label randomized, controlled trial, Clin Infect Dis, 64, 166, 10.1093/cid/ciw706 · DOI
- Heidari, 2012, In vivo susceptibility of Plasmodium vivax to chloroquine in southeastern Iran, Iran J Parasitol, 7, 8
- Douglas, 2010, Artemisinin combination therapy for vivax malaria, Lancet Infect Dis, 10, 405, 10.1016/S1473-3099(10)70079-7 · DOI · Paper page
- Thriemer, 2017, Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group, Malar J, 16, 141, 10.1186/s12936-017-1784-1 · DOI · Paper page
- Douglas, 2017, Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: a hospital-based cohort study, PLoS Med, 14, e1002379, 10.1371/journal.pmed.1002379 · DOI · Paper page
- Ursing, 2014, Chloroquine is grossly under dosed in young children with malaria: implications for drug resistance, PLoS One, 9, e86801, 10.1371/journal.pone.0086801 · doi:10.1371/journal.pone.0086801
- Obua, 2008, Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen, Br J Clin Pharmacol, 65, 493, 10.1111/j.1365-2125.2007.03050.x · doi:10.1111/j.1365-2125.2007.03050.x
- Zhao, 2014, Population pharmacokinetics of azithromycin and chloroquine in healthy adults and paediatric malaria subjects following oral administration of fixed-dose azithromycin and chloroquine combination tablets, Malar J, 13, 36, 10.1186/1475-2875-13-36 · doi:10.1186/1475-2875-13-36
- Añez, 2016, Evaluation of the paediatric dose of chloroquine in the treatment of Plasmodium vivax malaria, Malar J, 15, 371, 10.1186/s12936-016-1420-5 · doi:10.1186/s12936-016-1420-5
- Kofoed, 2002, Treatment of children with Plasmodium falciparum malaria with chloroquine in Guinea-Bissau, Am J Trop Med Hyg, 67, 28, 10.4269/ajtmh.2002.67.28 · doi:10.4269/ajtmh.2002.67.28
- Kofoed, 2007, Different doses of amodiaquine and chloroquine for treatment of uncomplicated malaria in children in Guinea-Bissau: implications for future treatment recommendations, Trans R Soc Trop Med Hyg, 101, 231, 10.1016/j.trstmh.2006.05.008 · DOI
- Ursing, 2016, High-dose chloroquine for treatment of chloroquine-resistant Plasmodium falciparum Malaria, J Infect Dis, 213, 1315, 10.1093/infdis/jiv590 · doi:10.1093/infdis/jiv590
- Ursing, 2009, Chloroquine is grossly overdosed and overused but well tolerated in Guinea-Bissau, Antimicrob Agents Chemother, 53, 180, 10.1128/AAC.01111-08 · doi:10.1128/aac.01111-08
- Scragg, 1968, Emetine hydrochloride and dehydroemetine combined with chloroquine in the treatment of children with amoebic liver abscess, Arch Dis Child, 43, 121, 10.1136/adc.43.227.121 · doi:10.1136/adc.43.227.121
- Canete, 2010, A randomized, controlled, open-label trial evaluating the efficacy and safety of chloroquine in the treatment of giardiasis in children, West Indian Med J, 59, 607
- Price, 2012, Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax, Trends Parasitol, 28, 522, 10.1016/j.pt.2012.08.005 · DOI
- White, 2002, The assessment of antimalarial drug efficacy, Trends Parasitol, 18, 458, 10.1016/S1471-4922(02)02373-5 · DOI · Paper page
- Flegg, 2011, Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator, Malar J, 10, 339, 10.1186/1475-2875-10-339 · DOI · Paper page
- Stepniewska, 2010, In vivo parasitological measures of artemisinin susceptibility, J Infect Dis, 201, 570, 10.1086/650301 · DOI · Paper page
Cited by
Getu, E., Biruksew, A., Eshetu, T., Abamecha, A., Assefa, D. G., Mohammed, H., Wuletaw, Y., Tasew, G., Tollera, G., Hailu, M., et al. (2025) · Malaria Journal · doi:10.1186/s12936-025-05446-y · Cited by 4
Metadata
- Authors
- Commons, R. J., Simpson, J. A., Thriemer, K., Humphreys, G. S., Abreha, T., Alemu, S. G., Añez, A., Anstey, N. M., Awab, G. R., Baird, J. K., Barber, B. E., Borghini-Fuhrer, I., Chu, C. S., D'Alessandro, U., Dahal, P., Daher, A., de Vries, P. J., Erhart, A., Gomes, M. S. M., Gonzalez-Ceron, L., Grigg, M. J., Heidari, A., Hwang, J., Kager, P. A., Ketema, T., Khan, W. A., Lacerda, M. V. G., Leslie, T., Ley, B., Lidia, K., Monteiro, W. M., Nosten, F., Pereira, D. B., Phan, G. T., Phyo, A. P., Rowland, M., Saravu, K., Sibley, C. H., Siqueira, A. M., Stepniewska, K., Sutanto, I., Taylor, W. R. J., Thwaites, G., Tran, B. Q., Tran, H. T., Valecha, N., Vieira, J. L. F., Wangchuk, S., William, T., Woodrow, C. J., Zuluaga-Idarraga, L., Guerin, P. J., White, N. J., & Price, R. N.
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 18
- Issue
- 9
- Pages
- 1025-1034
- ISSN
- 1473-3099
- Cited by
- 102
- References
- 0
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- Royal Australasian College of Physicians (1104975)
- Exxon Mobil Corporation
- National Health and Medical Research Council
- Bill and Melinda Gates Foundation (1135820, OPP1054404, OPP1164105)
- Pan American Health Organization
- United States Agency for International Development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. https://app.cochat.ai/papers/10.1016/s1473-3099(18)30348-7
- The paper
- Commons, R. J., Simpson, J. A., Thriemer, K., Humphreys, G. S., Abreha, T., Alemu, S. G., Añez, A., Anstey, N. M., Awab, G. R., Baird, J. K., Barber, B. E., Borghini-Fuhrer, I., Chu, C. S., D'Alessandro, U., Dahal, P., Daher, A., de Vries, P. J., Erhart, A., Gomes, M. S. M., . . . Price, R. N. (2018). The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(18)30348-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.